1.
Kardiologiia
; 51(9): 22-8, 2011.
Article
in Russian
| MEDLINE
| ID: mdl-22141186
Subject(s)
Blood Pressure/drug effects , Drugs, Generic/pharmacokinetics , Hypertension/drug therapy , Tetrazoles/pharmacokinetics , Valine/analogs & derivatives , Antihypertensive Agents/administration & dosage , Antihypertensive Agents/adverse effects , Antihypertensive Agents/pharmacokinetics , Drug Monitoring , Drugs, Generic/administration & dosage , Drugs, Generic/adverse effects , Female , Humans , Hypertension/physiopathology , Male , Middle Aged , Risk Factors , Severity of Illness Index , Single-Blind Method , Tetrazoles/administration & dosage , Tetrazoles/adverse effects , Therapeutic Equivalency , Treatment Outcome , Valine/administration & dosage , Valine/adverse effects , Valine/pharmacokinetics , Valsartan
2.
Kardiologiia
; 51(11): 38-44, 2011.
Article
in Russian
| MEDLINE
| ID: mdl-22117769
ABSTRACT
We gave perindopril (10 mg/day) for 24 weeks to 30 patients with arterial hypertension and obesity and proved its ability to effectively lower arterial pressure, exert cardio-, angio-, and nephro-protection, improve parameters of lipid, carbohydrate and purine metabolisms in these patients. Moreover perindopril in these patients diminished manifestations of insulin resistance, hyperleptinemia, and inflammation; it also exerted pronounced positive effect on anthropometric parameters and percent of fat deposits. Basing on the aggregate of clinical and pharmacodynamics effects perindopril can be considered the drug of choice for treatment of arterial hypertension at the background of obesity.